WuXi STA launches parenteral formulation manufacturing line at Wuxi
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This product is based on Osmotic Controlled Release Oral Delivery System technology
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
40,000 visitors and representatives of more than 80 countries set to visit the show
She will provide strategic advice and scientific leadership to support clients in clinical development, registration strategy, submission, early post-approval strategy
Subscribe To Our Newsletter & Stay Updated